A Bayesian basket trial design using a calibrated Bayesian hierarchical model
暂无分享,去创建一个
[1] Donald A Berry,et al. The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research , 2015, Molecular oncology.
[2] A. Redig,et al. Basket trials and the evolution of clinical trial design in an era of genomic medicine. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] David J Spiegelhalter,et al. A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.
[4] D. Berry,et al. Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials , 2013, Clinical trials.
[5] L. Billingham,et al. Research methods to change clinical practice for patients with rare cancers. , 2016, The Lancet. Oncology.
[6] P. Thall,et al. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.
[7] D. Sargent,et al. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Ying Yuan,et al. Bayesian Designs for Phase I-II Clinical Trials , 2016 .
[9] P. Thall,et al. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes , 2003, Statistics in medicine.
[10] S. Ornes. Core Concept: Basket trial approach capitalizes on the molecular mechanisms of tumors , 2016, Proceedings of the National Academy of Sciences.
[11] M. A. Pierotti,et al. Rearrangements of NTRK1 gene in papillary thyroid carcinoma , 2010, Molecular and Cellular Endocrinology.
[12] Ying Yuan,et al. BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity , 2018 .
[13] Richard Simon,et al. Implementing personalized cancer genomics in clinical trials , 2013, Nature Reviews Drug Discovery.
[14] B. Freidlin,et al. Borrowing Information across Subgroups in Phase II Trials: Is It Useful? , 2013, Clinical Cancer Research.